In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Case You Missed It: Top 10 "Gray Sheet" Stories In December

This article was originally published in The Gray Sheet

Executive Summary

Our most popular stories in December included an in-depth exploration of best practices in setting up an effective "war room" during an FDA inspection; a detailed look at user-fee reauthorization proposals early in the negotiation process; updates from the agency's Office of Regulatory Affairs, Office of Compliance, and Office of Device Evaluation; and more.

You may also be interested in...



New Fundings And Goals To Match Raised In Latest MDUFA IV Session

As the number of de novo applications and pre-submission consultations keep growing, FDA is proposing to institute provide new funding for these programs, among a range of additional proposals laid out in a recent closed-door negotiation. The agency's plan aligns somewhat with an industry proposal, according to meeting minutes, but there is also a lot to negotiate.

'Patent Troll' Turned Away By PTO In St. Jude Case

A patent review board found that a remote monitoring patent owned by a “non-practicing entity” was invalid due to obviousness. So-called "patent troll" cases had been relatively rare in the device arena, but there has been an increase in activity.

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

MT034562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel